Simon Paul
Clinical Professor
Infectious Diseases- Fresno
School of Medicine

Simon Paul, M.D.

Show full bio (70 words) Hide full bio

Associate Professor, UCSF Assistant Dean for Academic Affairs, UCSF Fresno HIV Director, UCSF Fresno Medical Director, Special Services, Community Regional Medical Center

Simon Paul, M.D., specializes in Infectious Diseases and HIV. He is board certified in Internal Medicine. His fellowship training was with NIH Physicians Scientist Fellowship at the Rockefeller University. He attended medical school at Cornell University Medical College and completed his residency training at Parkland Memorial Hospital.

Grants and Projects

Show all (2) Hide

• Change in Lactate Metabolism on Antiretroviral Therapy, NIH, 2004-2007
• Variant Surface Glycoproteins of Trypanosoma Cruzi, NIH, 1992-1997

Publications (6)

Top publication keywords:
DNA DamageHIV InfectionsAbscessDeoxyguanosineCoccidioidomycosisHIV Protease InhibitorsAIDS-Related Opportunistic InfectionsSarcoma, KaposiAmphotericin BImmune Reconstitution Inflammatory SyndromeAntiretroviral Therapy, Highly ActiveFluconazoleAcquired Immunodeficiency SyndromeCentral Nervous System Fungal InfectionsAnti-HIV Agents

• Immune Reconstitution Inflammatory Syndrome in Patients with AIDS and Disseminated Coccidioidomycosis: A Case Series and Review of the Literature.
  Journal of the International Association of Providers of AIDS Care 2017 Mu A, Shein TT, Jayachandran P, Paul S
• Sertraline demonstrates fungicidal activity in vitro for Coccidioides immitis.
  Mycology 2016 Paul S, Mortimer RB, Mitchell M
• Incidence of Kaposi's sarcoma and associated mortality in Fresno, California, 1998 to 2012.
  Journal of the International Association of Providers of AIDS Care 2014 Mu A, Rutledge J, Mills P, Paul S
• Urinary 8-hydroxy-2'-deoxyguanosine, a metabolite of oxidized DNA, is not elevated in HIV patients on combination antiretroviral therapy.
  Free radical research 2003 Paul S, Bogdanov MB, Matson WR, Metakis L, Jacobs J, Beal MF
• Brief report: efficacy and treatment-limiting toxicity with the concurrent use of lopinavir/ritonavir and a third protease inhibitor in treatment-experienced HIV-infected patients.
  Journal of acquired immune deficiency syndromes (1999) 2003 Casau NC, Glesby MJ, Paul S, Gulick RM
• Impact of antiretroviral therapy on decreasing hospitalization rates of HIV-infected patients in 2001.
  AIDS research and human retroviruses 2002 Paul S, Gilbert HM, Lande L, Vaamonde CM, Jacobs J, Malak S, Sepkowitz KA